Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gopa Iyer

Showing results (71-80 of 144) with videos related to

Pageof 15
Sort By:
Plos Medicine|May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysisAlexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.
The Lancet. Oncology|August 4, 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Martin Schuler, Gopa Iyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in CancerSabine Topka, Zoe Steinsnyder, Vignesh Ravichandran, et al.
The American Journal of Surgical Pathology|May 29, 2019
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available AntibodiesHenning Reis, Rene Serrette, Jennifer Posada, et al.
Cancer|August 2, 2016
Genomic characterization of response to chemoradiation in urothelial bladder cancerNeil B Desai, Sasinya N Scott, Emily C Zabor, et al.
European Urology Oncology|March 30, 2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell CarcinomaRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Human Pathology|March 31, 2018
Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinomaSumit Isharwal, Hongying Huang, Gouri Nanjangud, et al.
European Urology|August 6, 2014
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladderPhilip H Kim, Eugene K Cha, John P Sfakianos, et al.
JCO Precision Oncology|July 1, 2025
Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601Gopa Iyer, Woonyoung Choi, Bin Luo, et al.
Nature Genetics|July 18, 2018
Genome doubling shapes the evolution and prognosis of advanced cancersCraig M Bielski, Ahmet Zehir, Alexander V Penson, et al.
Pageof 15

Showing results (71-80 of 144) with videos related to

Sort By:
Pageof 15
Plos Medicine|May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysisAlexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.
The Lancet. Oncology|August 4, 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Martin Schuler, Gopa Iyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in CancerSabine Topka, Zoe Steinsnyder, Vignesh Ravichandran, et al.
The American Journal of Surgical Pathology|May 29, 2019
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available AntibodiesHenning Reis, Rene Serrette, Jennifer Posada, et al.
Cancer|August 2, 2016
Genomic characterization of response to chemoradiation in urothelial bladder cancerNeil B Desai, Sasinya N Scott, Emily C Zabor, et al.
European Urology Oncology|March 30, 2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell CarcinomaRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Human Pathology|March 31, 2018
Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinomaSumit Isharwal, Hongying Huang, Gouri Nanjangud, et al.
European Urology|August 6, 2014
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladderPhilip H Kim, Eugene K Cha, John P Sfakianos, et al.
JCO Precision Oncology|July 1, 2025
Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601Gopa Iyer, Woonyoung Choi, Bin Luo, et al.
Nature Genetics|July 18, 2018
Genome doubling shapes the evolution and prognosis of advanced cancersCraig M Bielski, Ahmet Zehir, Alexander V Penson, et al.
Pageof 15